Monitoring interactions between receptor tyrosine kinases and their downstream effector proteins in living cells using bioluminescence resonance energy transfer

Molecular Pharmacology

Volumn 72, Issue 6, 2007, Pages 1440-1446

  Tan, Philip K ^a   Wang, Jean ^a   Littler, Pey Lih H ^a   Wong, Kenneth K ^a   Sweetnam, Timothy A ^a   Keefe, William ^a   Nash, Norman R ^a   Reding, Esther C ^a   Piu, Fabrice ^a   Brann, Mark R ^a   Schiffer, Hans H ^a  

^a ACADIA PHARMACEUTICALS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRAIN DERIVED NEUROTROPHIC FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; GROWTH FACTOR RECEPTOR BOUND PROTEIN 2; IMATINIB; PHOSPHOLIPASE C GAMMA; PLATELET DERIVED GROWTH FACTOR; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; PLATELET DERIVED GROWTH FACTOR BB; POLYPEPTIDE; PROTEIN P85; PROTEIN SHC; PROTEIN TYROSINE KINASE; STAT5A PROTEIN; TYROSINE; VASCULOTROPIN;

ARTICLE; AUTOPHOSPHORYLATION; BIOLUMINESCENCE RESONANCE ENERGY TRANSFER; CARBOXY TERMINAL SEQUENCE; CONTROLLED STUDY; EFFECTOR CELL; ENZYME ACTIVITY; ERYTHROLEUKEMIA; GASTROINTESTINAL STROMAL TUMOR; HUMAN; HUMAN CELL; MUTATION; ONCOGENE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN PROTEIN INTERACTION; QUANTITATIVE ANALYSIS; SENSITIVITY ANALYSIS; SEQUENCE HOMOLOGY; SIGNAL TRANSDUCTION; TECHNOLOGY; WHOLE CELL;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ANIMALS; CELL LINE; FLUORESCENCE RESONANCE ENERGY TRANSFER; HUMANS; LUMINESCENT PROTEINS; PROTEIN BINDING; RECEPTOR PROTEIN-TYROSINE KINASES; RENILLA;

EID: 36349023324     PISSN: 0026895X     EISSN: 15210111     Source Type: Journal    
DOI: 10.1124/mol.107.039636     Document Type: Article

References (23)

1. Angers S, Salahpour A, Joly E, Hilairet S, Chelsky D, Dennis M, and Bouvier M (2000) Detection of beta 2-adrenergic receptor dimerization in living cells using bioluminescence resonance energy transfer (BRET). Proc Natl Acad Sci U S A 97:3684-3689.
2. Bild AH, Yao G, Chang JT, Wang Q, Potti A, Chasse D, Joshi MB, Harpole D, Lancaster JM, Berchuck A, et al. (2006) Oncogenic pathway signatures in human cancers as a guide to targeted therapies. Nature 439:353-357.
3. Blanquart C, Boute N, Lacasa D, and Issad T (2005) Monitoring the activation state of the insulin-like growth factor-1 receptor and its interaction with protein tyrosine phosphatase 1B using bioluminescence resonance energy transfer. Mol Pharmacol 68:885-894.
4. Blanquart C, Gonzalez-Yanes C, and Issad T (2006) Monitoring the activation state of insulin/insulin-like growth factor-1 hybrid receptors using bioluminescence resonance energy transfer. Mol Pharmacol 70:1802-1811.
5. Heinrich MC, Corless CL, Demetri GD, Blanke CD, von Mehren M, Joensuu H, McGreevey LS, Chen CJ, Van den Abbeele AD, Druker BJ, et al. (2003a) Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol 21:4342-4349.
6. Heinrich MC, Corless CL, Duensing A, McGreevey L, Chen CJ, Joseph N, Singer S, Griffith DJ, Haley A, Town A, et al. (2003b) PDGFRA activating mutations in gastrointestinal stromal tumors. Science 299:708-710.
7. Heldin CH (1995) Dimerization of cell surface receptors in signal transduction. Cell 80:213-223.
8. Jordan M, Schallhorn A, and Wurm FM (1996) Transfecting mammalian cells: optimization of critical parameters affecting calcium-phosphate precipitate formation. Nucleic Acids Res 24:596-601.
9. Krause DS and Van Etten RA (2005) Tyrosine kinases as targets for cancer therapy. N Engl J Med 353:172-187.
10. Minor LK (2005) Assays for membrane tyrosine kinase receptors: methods for high-throughput screening and utility for diagnostics. Expert Rev Mol Diagn 5:561-571.
11. Nouaille S, Blanquart C, Zilberfarb V, Boute N, Perdereau D, Burnol AF, and Issad T (2006a) Interaction between the insulin receptor and Grb14: a dynamic study in living cells using BRET. Biochem Pharmacol 72:1355-1366.
12. Nouaille S, Blanquart C, Zilberfarb V, Boute N, Perdereau D, Roix J, Burnol AF, and Issad T (2006b) Interaction with Grb14 results in site-specific regulation of tyrosine phosphorylation of the insulin receptor. EMBO Rep 7:512-518.
13. Olive DM (2004) Quantitative methods for the analysis of protein phosphorylation in drug development. Expert Rev Proteomics 1:327-341.
14. Pao W and Miller VA (2005) Epidermal growth factor receptor mutations, small-molecule kinase inhibitors, and non-small-cell lung cancer: current knowledge and future directions. J Clin Oncol 23:2556-2568.
15. Pfleger KD and Eidne KA (2006) Illuminating insights into protein-protein interactions using bioluminescence resonance energy transfer (BRET). Nat Methods 3:165-174.
16. Robinson DR, Wu YM, and Lin SF (2000) The protein tyrosine kinase family of the human genome. Oncogene 19:5548-5557.
17. Sawyer TK, Bohacek RS, Metcalf CA 3rd, Shakespeare WC, Wang Y, Sundaramoorthi R, Keenan T, Narula S, Weigele M, and Dalgarno DC (2003) Novel protein kinase inhibitors: SMART drug design technology. Biotechniques Suppl:2-10, 12-5.
18. Sawyers C (2004) Targeted cancer therapy. Nature 432:294-297.
19. Schiffer HH, Reding EC, Fuhs SR, Lu Q, Piu F, Wong S, Littler PL, Weiner DM, Keefe W, Tan PK, et al. (2007) Pharmacology and signaling properties of epidermal growth factor receptor isoforms studied by bioluminescence resonance energy transfer. Mol Pharmacol 71:508-518.
20. Schlessinger J (2000) Cell signaling by receptor tyrosine kinases. Cell 103:211-225.
21. Schlessinger J and Lemmon MA (2003) SH2 and PTB domains in tyrosine kinase signaling. Sci STKE 2003:RE12.
22. Schulze WX, Deng L, and Mann M (2005) Phosphotyrosine interactome of the ErbB-receptor kinase family. Mol Syst Biol 1:2005.0008.
23. Xu Y, Piston DW, and Johnson CH (1999) A bioluminescence resonance energy transfer (BRET) system: application to interacting circadian clock proteins. Proc Natl Acad Sci U S A 96:151-156.